The global meningococcal vaccines market size is worth around USD 5,119 million in 2024 and is predicted to hit around USD 9,254 million by 2034, growing at a CAGR of 6.1% from 2024 to 2034.
The meningococcal vaccine market is a prominent segment of the healthcare industry. This industry deals in the manufacturing and distribution of vaccines used for preventing meningococcal diseases. There are different types of meningococcal vaccines available in the market consisting of bivalent vaccines, quadrivalent vaccines, and some others. These vaccines are distinguished based on serotype comprising serotype A, serotype B, serotype C, serotype W-135, and serotype Y. The increased prevalence of meningitis has driven the market growth. This market is expected to rise significantly with the growth of the biopharmaceutical industry across the globe.
The rising awareness related to the seriousness of meningococcal disease among the general public and healthcare professionals has boosted the market growth. Also, the surge in several government initiatives aimed at developing the healthcare infrastructure coupled with rapid advances in the biopharma industry has played a crucial role in shaping the industrial landscape. Moreover, the growing demand for these vaccines from several end-users consisting of public health agencies, communities, clinics, and some others is predicted to drive the growth of the meningococcal vaccines market. The research and development activities related to conjugate vaccines along with advancements in gene editing technologies iareexpected to create ample growth opportunities for the market players in the future.
Published by Deepa Pandey
